{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:50:23Z","timestamp":1792108223373,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10928-026-10042-x","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:06:57Z","timestamp":1783782417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Longitudinal Disease Progression Model Characterizing Endoscopic Response and Remission in Crohn\u2019s Disease"],"prefix":"10.1007","volume":"53","author":[{"given":"Anita","family":"Moein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Langenhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nastya","family":"Kassir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"issue":"24","key":"10042_CR1","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.3748\/wjg.v27.i24.3440","volume":"27","author":"A Aksan","year":"2021","unstructured":"Aksan A, Farrag K, Blumenstein I, Schr\u00f6der O, Dignass AU, Stein J (2021) Chronic intestinal failure and short bowel syndrome in Crohn\u2019s disease. World J Gastroenterol 27(24):3440\u20133465. https:\/\/doi.org\/10.3748\/wjg.v27.i24.3440 PMID: 34239262; PMCID: PMC8240052","journal-title":"World J Gastroenterol"},{"key":"10042_CR2","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","volume":"380","author":"DC Baumgart","year":"2012","unstructured":"Baumgart DC, Sandborn WJ (2012) Crohn\u2019s disease. Lancet 380:1590\u20131605","journal-title":"Lancet"},{"key":"10042_CR3","doi-asserted-by":"publisher","unstructured":"Daperno M, D\u2019Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P (2004) Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD. Gastrointest Endosc. ;60(4):505\u2009\u2013\u200912. https:\/\/doi.org\/10.1016\/s0016-5107(04)01878-4. PMID: 15472670","DOI":"10.1016\/s0016-5107(04)01878-4"},{"key":"10042_CR4","doi-asserted-by":"publisher","unstructured":"Moein A, Langenhorst J, Plan EL, Jin JY, K\u00e5gedal M, Kassir N (2023) A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score. Clin Transl Sci. ;16(11):2310\u20132322. doi: 10.1111\/cts.13632. Epub 2023 Sep 22. Erratum in: Clin Transl Sci. 2024;17(5):e13814. https:\/\/doi.org\/10.1111\/cts.13814. PMID: 37718498; PMCID: PMC10651636","DOI":"10.1111\/cts.13814"},{"issue":"1","key":"10042_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S2468-1253(22)00303-X","volume":"8","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Panes J, Danese S, Sharafali Z, Hassanali A, Jacob-Moffatt R et al (2023) Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn\u2019s disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 8(1):43\u201355","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10042_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1208\/s12248-019-0343-9","volume":"21","author":"GJ Wellhagen","year":"2019","unstructured":"Wellhagen GJ, Kjellsson MC, Karlsson MO (2019) A Bounded Integer Model for Rating and Composite Scale Data. AAPS J 21:74","journal-title":"AAPS J"},{"key":"10042_CR7","unstructured":"Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ (2018) NONMEM 7.4.1 users guides (1989-2018). Hanover, MD, ICON Development Solutions"},{"key":"10042_CR8","unstructured":"https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/crohns-disease-developing-drugs-treatment. Accessed Oct 2025"},{"issue":"9","key":"10042_CR9","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1136\/gutjnl-2015-309903","volume":"65","author":"L Vuitton","year":"2016","unstructured":"Vuitton L, Marteau P, Sandborn WJ, Levesque BG, Feagan B, Vermeire S, Danese S, D\u2019Haens G, Lowenberg M, Khanna R, Fiorino G, Travis S, Mary JY, Peyrin-Biroulet L (2016) IOIBD technical review on endoscopic indices for Crohn\u2019s disease clinical trials. Gut 65(9):1447\u20131455. https:\/\/doi.org\/10.1136\/gutjnl-2015-309903 Epub 2015 Sep 9. PMID: 26353983","journal-title":"Gut"},{"key":"10042_CR10","doi-asserted-by":"crossref","unstructured":"Lyauk YK, Jonker DM, Lund TM, Hooker AC, Karlsson MO (2020) Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. AAPS J 22 115","DOI":"10.1208\/s12248-020-00500-w"},{"issue":"3","key":"10042_CR11","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1208\/s12248-017-0058-8","volume":"19","author":"G Gottipati","year":"2017","unstructured":"Gottipati G, Karlsson MO, Plan EL (2017) Modeling a Composite Score in Parkinson\u2019s Disease Using Item Response Theory. AAPS J 19(3):837\u2013845. https:\/\/doi.org\/10.1208\/s12248-017-0058-8 Epub 2017 Feb 28. PMID: 28247193","journal-title":"AAPS J"},{"issue":"8","key":"10042_CR12","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1002\/psp4.13190","volume":"13","author":"EN Jonsson","year":"2024","unstructured":"Jonsson EN, Nyberg J (2024) Full random effects models (FREM): A practical usage guide. CPT Pharmacometrics Syst Pharmacol 13(8):1297\u20131308. https:\/\/doi.org\/10.1002\/psp4.13190 Epub 2024 Jun 27. PMID: 38937897; PMCID: PMC11330183","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10042_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/psp4.12741","volume":"11","author":"G Yngman","year":"2022","unstructured":"Yngman G, Nyberg HB, Nyberg J, Jonsson EN, Karlsson MO (2022) An introduction to the full random effects model. CPT Pharmacometrics Syst Pharmacol 11:149\u2013160. https:\/\/doi.org\/10.1002\/psp4.12741","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10042_CR14","doi-asserted-by":"crossref","unstructured":"Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming. Comput Methods Programs Biomed. ;75(2):85\u201394. doi: 10.1016\/j.cmpb.2003.11.003.","DOI":"10.1016\/j.cmpb.2003.11.003"},{"key":"10042_CR15","unstructured":"R Core Team (2019) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/"},{"key":"10042_CR16","unstructured":"https:\/\/github.com\/pharmetheus\/PMXFrem"},{"key":"10042_CR17","unstructured":"https:\/\/github.com\/pharmetheus\/PMXForest"},{"issue":"3","key":"10042_CR18","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 11(3):558\u2013569. https:\/\/doi.org\/10.1208\/s12248-009-9133-0 Epub 2009 Aug 1. PMID: 19649712; PMCID: PMC2758126","journal-title":"AAPS J"},{"issue":"1","key":"10042_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3904\/kjim.2016.324","volume":"34","author":"YW Lee","year":"2019","unstructured":"Lee YW, Lee KM, Lee JM, Chung YY, Kim DB, Kim YJ, Chung WC, Paik CN (2019) The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity. Korean J Intern Med 34(1):72\u201380. https:\/\/doi.org\/10.3904\/kjim.2016.324 Epub 2018 Jan 20. PMID: 29347813; PMCID: PMC6325438","journal-title":"Korean J Intern Med"},{"key":"10042_CR20","doi-asserted-by":"crossref","unstructured":"Ma C, Battat R, Khanna R, Parker CE, Brian G, Feagan (2019) Vipul Jairath, What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn\u2019s disease activity? Best Practice & Research Clinical Gastroenterology, Volumes 38\u201339, 101602, ISSN 1521\u20136918","DOI":"10.1016\/j.bpg.2019.02.004"},{"key":"10042_CR21","doi-asserted-by":"publisher","unstructured":"Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ (2007) Certolizumab pegol for active Crohn\u2019s disease. N Engl J Med. ;357(3):228\u2013238. https:\/\/doi.org\/10.1056\/NEJMoa067594","DOI":"10.1056\/NEJMoa067594"},{"issue":"10114","key":"10042_CR22","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","volume":"390","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vanasek T, Danalioglu A, Novacek G, Armuzzi A, Hebuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ (2017) Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. ;390(10114):2779\u20132789. https:\/\/doi.org\/10.1016\/S0140-6736(17)32641-7","journal-title":"Lancet"},{"key":"10042_CR23","doi-asserted-by":"publisher","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A, GEMINI 2 Study Group (2013). Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. ;369(8):711\u2009\u2013\u200921. https:\/\/doi.org\/10.1056\/NEJMoa1215739","DOI":"10.1056\/NEJMoa1215739"},{"key":"10042_CR24","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00555-3","author":"GJ Wellhagen","year":"2021","unstructured":"Wellhagen GJ, Ueckert S, Kjellsson MC, Karlsson MO (2021) AAPS J 23(3):45. https:\/\/doi.org\/10.1208\/s12248-021-00555-3"},{"key":"10042_CR26","unstructured":"https:\/\/www.fda.gov\/drugs\/development-resources\/model-informed-drug-development-paired-meeting-program. Accessed Oct 2025"},{"key":"10042_CR27","unstructured":"International Council for Harmonisation (ICH). M15 General Principles for Model-Informed Drug Development. Draft version endorsed on November 6 (2024) ICH Harmonised Guideline. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2024. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/m15-general-principles-model-informed-drug-development. Accessed October 2025"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10042-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-026-10042-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10042-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:21:46Z","timestamp":1792106506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-026-10042-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10042"],"URL":"https:\/\/doi.org\/10.1007\/s10928-026-10042-x","relation":{"references":[{"id-type":"doi","id":"10.1208\/s12248-021-00555-3","asserted-by":"subject"}]},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"15 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M. and N.K. are Genentech employees and Roche shareholders. J. L. is an employee of Pharmetheus AB and is a paid consultant for Genentech, Inc.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"38"}}